story of the week
Personalized Response-Directed Surgery and Adjuvant Therapy After Neoadjuvant Ipilimumab and Nivolumab in High-Risk Stage III Melanoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Nature Medicine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial
Nat. Med. 2022 Jun 05;[EPub Ahead of Print], ILM Reijers, AM Menzies, ACJ van Akkooi, JM Versluis, NMJ van den Heuvel, RPM Saw, TE Pennington, E Kapiteijn, AAM van der Veldt, KPM Suijkerbuijk, GAP Hospers, EA Rozeman, WMC Klop, WJ van Houdt, K Sikorska, JA van der Hage, DJ Grünhagen, MW Wouters, AJ Witkamp, CL Zuur, JM Lijnsvelt, A Torres Acosta, LG Grijpink-Ongering, M Gonzalez, K Jóźwiak, C Bierman, KF Shannon, S Ch'ng, AJ Colebatch, AJ Spillane, JBAG Haanen, RV Rawson, BA van de Wiel, LV van de Poll-Franse, RA Scolyer, AH Boekhout, GV Long, CU BlankFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.